Under this agreement, Innovaro will provide technology search and evaluation services for Core Oncology, identifying new and complementary technologies to strengthen their portfolio of cancer treatment therapies. Working closely with Core Oncology’s leadership, Innovaro will identify new and complementary technologies for potential acquisition, conduct landscape and competitive analysis on a range of technology areas, and provide strategic recommendations related to their IP portfolio.

“The technology and research landscape in cancer therapies is vast and having an expert who can help us understand and navigate the possibilities is crucial to our business.” Travis Gay, CEO and president of Core Oncology continued, “With Innovaro as our partner, we will be able to accelerate our development and delivery of cancer therapies, while remaining focused on our core products and customers.”

“We’re excited about this opportunity to work with Core Oncology in the advancement of cancer therapies. Their early market success with prostate brachytherapy and their focus on the localisation of cancer treatments provides challenging and meaningful work for us,” stated Bill Cawley, senior vice president of Innovaro. “The cancer therapeutics market is growing rapidly, which means this will be both interesting and potentially very rewarding work for Innovaro and our client Core Oncology.”

“Verdant Ventures is excited about the opportunities presented by Core Oncology. We believe that combining the resources of Verdant Ventures and Innovaro will provide Core Oncology with the expertise to enable continued and expanded success moving forward,” stated John Micek, manager of Verdant Ventures. “We’re finding that the Innovaro and Verdant Venture team is resonating in the market and this deal demonstrates it.”